Drug intelligence / Profile preview

GC5136A

Development stage: Preclinical
Lead developer: GC Biopharma

Overview

GC5136A is an investigational drug candidate currently in preclinical development by GC Biopharma (formerly Green Cross) for the treatment of immunodeficiency. Positioned within the company's immunology portfolio, which includes established immunoglobulin-based therapies such as Aliglo (GC5107B), GC5136A is being evaluated for its potential to address immune system disorders. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed, it represents a next-generation approach in the company's pipeline for primary or secondary immunodeficiency conditions.

Beyond the preview

Go deeper on GC5136A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC5136A.

Explore the full profile